Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And there's the money raise at 1.50
Sold at 2.12. Only update today on the additional biomarker data was talking about peer reviews and conferences. I expected data at least a month ago. I'm concerned they'll raise money before we get any significant data updates. I could be making a mistake but taking profits from .79 so can't be too upset if I do. I'll buy back if it goes lower most likely. GLTA
I like Coya a lot as well. I was hoping to see how the Biogen data plays out here and then moving funds there. Hopefully I'll get that chance. I'm not sure COYA's next coming data will be ideal based on the dosage and other trial parameters but could give a great indication to set up a pivotal P3. Lot of bigger money over there. I've got my eyes on them for sure. JMHO
Suggest a look at $COYA for ALS.
Disappointed for the ALS community. Hoping NRSN can provide some hope.
https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-topline-results-120000695.html?guccounter=1&guce_referrer=YW5kcm9pZC1hcHA6Ly9jb20uZ29vZ2xlLmFuZHJvaWQuZ29vZ2xlcXVpY2tzZWFyY2hib3gv&guce_referrer_sig=AQAAAAM8h3Ee_7hkwe__ixrWmntWVPdxe8WZ1ZpxVn7ZSc5Y_cvU8dUOeH8gNnkII0GDb_rsadt-ieRtojdTcEbDoBluMPdmwoVEaO7k8HMPi6OgMQhLipitwShkj668qEiwBreTeVNkxishXrsTPgOOOMTmvMybqLk3QVA9AiTxt2Bt
If Biogen results are good then yes. If not then no lol. It's a gamble. I'm not buying at these levels but my cost basis is .795 so I don't have to.
NRSN.................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
NRSN........................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
I don't know about the biomarker data or any partnership discussions are going but this sure is a lot of volume in a positive fashion the last couple days.
Looks like additional good news today but the neurofilament results we have been imminently expecting are on track for some time this quarter, which could mean another 5 or 6 weeks. The question remains of how good those results are (or aren't) and if the company raises money before or after. JMHO
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Tues is the 20th I think....Any day.now?...tick tock....
Looks like the neurofilament light data in collaboration with Biogen isn't quite imminent as today's PR says the coming weeks fyi.
Could be tomorrow lol
Not sure the holdup on the neurofilament light data. Though it was supposed to be out in January
yeah looking forward to 2 dollars and up with volume and news
Quite a run today. Fingers crossed on the new data when released
Only what you can afford to lose. As risky as any.
How many shares do folks have in here...I was thinking of getting a few
Sounds Rational...In 6/22 it did a little more than 3x on 220 million shares...In December it tripled on much smaller volume...Then again in 6/22 ,I guess it could have went a lot higher in pre- mkt/after-hours,maybe that kinda explains the huge volume....idk seems to have potential for a good rip
I don't honestly know. It's seen huge profit taking every time they've put out positive news. Traders/shorters, who knows. The company needs money to advance and when that's the case you see wild swings. The ball is in Biogen's court it would seem. All depends on the biomarker results we should get at any time.
hey Runn....What caused Nrsn to dip.between Dec 4th-6th...just curious
Supposedly they are fully funded into Q2 24'.....As of October 4....There was 22-26 million shares that went buy as the share price declined a bit in December...Maybe it's nothing..."We are optimistic about our mechanisms of action... anticipated in Q4 of 23'".......Still kinda interested
..
This ticker looked pretty attractive until I noticed it was an Israeli one... Similar to Chinese, Israeli ones more often than not....Is it worth setting that factor aside?
Potentially yes as long as some of the biomarker data is good. We should find out about that data in the next week or two supposedly to the best of my understanding.
Is there a positive Catalyst Coming later this month?
you choice is display picture is what is in question, here why are you using that image
NRSN: How many time must I post this??? READ IT. I quoted the figures ACCURATELY. In any event, this JUNK STOCK is dead!! Let's all MOVE ON!!
https://www.google.com/search?q=is+als+a+rare+disease&sca_esv=588105669&source=hp&ei=an9vZdOZGevHkPIP2rCN8Aw&iflsig=AO6bgOgAAAAAZW-Nem49qIuR5YltejA1r0lBYMi_4ZKE&oq=is+als+a+ra&gs_lp=Egdnd3Mtd2l6IgtpcyBhbHMgYSByYSoCCAAyBRAAGIAEMgYQABgWGB4yCxAAGIAEGIoFGIYDMgsQABiABBiKBRiGA0iRL1AAWJ4YcAB4AJABAJgB0wKgAY4KqgEHNy4yLjEuMbgBAcgBAPgBAcICCxAAGIAEGLEDGIMBwgIOEC4YgAQYsQMYxwEY0QPCAgsQLhiABBjHARjRA8ICBRAuGIAEwgIREC4YgAQYsQMYgwEYxwEY0QPCAggQLhiABBixA8ICCBAAGIAEGLEDwgILEC4YxwEY0QMYgATCAg4QABiABBiKBRixAxiDAcICCxAuGIAEGLEDGIMBwgIXEC4YgAQYsQMYlwUY3AQY3gQY4ATYAQG6BgYIARABGBQ&sclient=gws-wiz
You were off somewhere between 30% and 600%. Do you know how much a patient pays a year for ALS medication? That would be quite a bit of difference in sales revenues. Either way potential sales, if ever, are quite a ways off no doubt. If Biogen takes over the indication would likely be much quicker through any approval process. JMHO
Do you need validation that bad? YOU stated it was EXTREMELY rare and I noted that I happen to know three people unrelated who got it so how EXTREMELY rare can that be? You want to get into semantics here? If I am a "moron" for stating a personal fact, then you are Infallible with a capital I.
WOW!!! I was off by 1/2-of-a-point!!!!!! GOD HELP ME!!!!! (The stolen-Nation of ISRAEL is shit, and so is this FIRM!!)
NRSN: I simply quoted what the NEWS & PR's published.
His facts were clearly wrong. Looks like Biogen could determine share price next year. Probably nothing to see here for the next 4-6 weeks imo
I don't know if I would call it an extremely RARE disorder since I personally know of three people who got it and none of them were related.
Let the PRICE of this determine who is WRONG; and I will leave at that. HAVE A NICE DAY!!
It's early in the process. I don't have a dog in the fight at this point but it's the Biogen connection that intrigues me as we await additional biomarker data.
You're not only wrong but you're two orders of magnitude wrong.
NRSN: I am NOT "wrong". And moreover, the ISRAELI connection here will KILL this stock, as it is already doing. Watch & learn.
re: "only 1-to-3 cases out of any 100,000 peeps."
W R O N G
Roughly 1 in every 400 people will develop ALS in their lifetime. And evidence shows that ALS is much more common in older people.
https://www.als.net/news/1-in-400-how-many-people-will-get-als/
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
174
|
Created
|
01/21/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |